Last updated: March 31, 2025
Sponsor: Pfizer
Overall Status: Completed
Phase
N/A
Condition
Vaginal Infection
Hiv
Gynecological Infections
Treatment
MenACWY Vaccine
Trumenba Vaccine
Clinical Study ID
NCT05873751
B1971066
Ages 15-30 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Individuals of 15-30 years old registered in the PharMetrics Plus system
Individuals having the index vaccination event at the age of 15-30 in 2016-2021
Exclusion
Exclusion Criteria:
Individuals having any dose of Bexsero at any time during the study period and priorto the study
Individuals with incomplete information on variables to be collected.
Study Design
Total Participants: 1307378
Treatment Group(s): 2
Primary Treatment: MenACWY Vaccine
Phase:
Study Start date:
April 24, 2023
Estimated Completion Date:
March 31, 2024
Study Description
Connect with a study center
Pfizer
New York, New York 10001
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.